CAMBRIDGE, Mass., June 02, 2016 (GLOBE NEWSWIRE) -- CoLucid Pharmaceuticals, Inc. (Nasdaq:CLCD), a Phase 3 clinical-stage biopharmaceutical company that is developing lasmiditan oral tablets for the acute treatment of migraine in adults, announced today it will provide a corporate overview at the Jefferies 2016 Healthcare Conference, being held in New York City June 7-10, 2016.
| Jefferies 2016 Healthcare Conference | ||||
| Date: | Wednesday, June 8th | |||
| Time: | 3:30pm Eastern Time | |||
| Location: | New York City | |||
| Webcast: | http://wsw.com/webcast/jeff97/clcd | |||
About CoLucid Pharmaceuticals, Inc.
CoLucid was founded in 2005 and is developing oral lasmiditan for the acute treatment of migraine headaches in adults and intravenous lasmiditan for the acute treatment of headache pain associated with migraine in adults in emergency room and other urgent care settings.